Search research articles
Contact Us
Filters
Showing results (81-90 of 86) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 86 results.
Journal for Immunotherapy of Cancer
|
May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma
Evan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
The New England Journal of Medicine
|
December 22, 2018
Sorafenib for Advanced and Refractory Desmoid Tumors
Mrinal M Gounder, Michelle R Mahoney, Brian A Van Tine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2015
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Neeta Pandit-Taskar, Joseph A O'Donoghue, Jeremy C Durack, et al.
Journal for Immunotherapy of Cancer
|
June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
Sujana Movva, Kenneth Seier, Martina Bradic, et al.
Cancer Research Communications
|
December 1, 2025
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Evan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar, et al.
Cancer Discovery
|
November 23, 2018
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 86) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 86 results.
Journal for Immunotherapy of Cancer
|
May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma
Evan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
The New England Journal of Medicine
|
December 22, 2018
Sorafenib for Advanced and Refractory Desmoid Tumors
Mrinal M Gounder, Michelle R Mahoney, Brian A Van Tine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 16, 2015
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Neeta Pandit-Taskar, Joseph A O'Donoghue, Jeremy C Durack, et al.
Journal for Immunotherapy of Cancer
|
June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
Sujana Movva, Kenneth Seier, Martina Bradic, et al.
Cancer Research Communications
|
December 1, 2025
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Evan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar, et al.
Cancer Discovery
|
November 23, 2018
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, et al.
Page
of 9